Jihlava 1

• A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman … Not authorised
  2023-507633-21-00 5 Neurological Disease
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1
• A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting
  2024-512707-40-00 4 2024-11-07 RELAPSING MULTIPLE SCLEROSIS
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting
  2023-504358-36-00 5 2024-10-17 multiple sclerosis
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Ended recruitment
  2025-521127-73-00 5 2025-09-12 Relapsing forms of Multiple Sclerosis
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended recruitment
  2023-504827-17-00 5 2024-03-18 Chronic migraine
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis

Showing 1–24 of 44 trials